Lungs News and Research

RSS

Existing immunotherapy drug pembrolizumab shows promise for specific sarcoma subtypes

An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute.

7 Jun 2016

Study shows aggressive end-of-life care for young cancer patients may be less effective

In the last month of their lives, younger cancer patients continued to be hospitalized and receive other aggressive treatment at high rates, a University of North Carolina Lineberger Comprehensive Cancer Center-led study found.

7 Jun 2016

Disruptive sleep patterns could raise heart disease risk in shift workers and insomniacs

People who suffer from a lack of sleep and disordered sleep cycles could be increasing their chances of developing cardiovascular disease, according to a study in the American Heart Association’s Journal Hypertension.

7 Jun 2016

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial, researchers at the Abramson Cancer Center of the University of Pennsylvania and other institutions reported at the 2016 American Society of Clinical Oncology annual meeting.

7 Jun 2016

Researchers find increased cancer incidence among patients with primary immunodeficiency disorders

Primary immunodeficiency disorders are a group of more than 300 single gene defects that affect the role of the immune system and prevent it from functioning properly. When Roswell Park Cancer Institute researchers evaluated the overall and site-specific incidence of cancer among patients registered in the United States Immune Deficiency Network, they found increased cancer incidence rates among patients with primary immunodeficiency diseases — and, in particular, a significant increase in lymphoma cases.

7 Jun 2016

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

Ramucirumab is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours.

6 Jun 2016

Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Patients with recurrent high-grade glioma brain tumors have few effective treatment options and the majority of available therapies do not improve survival. Moffitt Cancer Center will present preliminary results from a phase 1 study testing whether the addition of pembrolizumab to radiation therapy and bevacizumab is safe and can control tumor growth for these patients.

6 Jun 2016

Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

A significant proportion of lung cancer patients also have autoimmune disease, which may make them unsuitable for increasingly popular immunotherapy treatments, a team of researchers at UT Southwestern Medical Center's Harold C. Simmons Comprehensive Cancer Center has found.

6 Jun 2016

Combination therapy equally good at treating small cell lung cancer

HAVING radiotherapy once a day for six and a half weeks or twice a day for three weeks -- when combined with chemotherapy -- is equally good at treating small cell lung cancer that hasn't spread.

6 Jun 2016

Experimental drug Rova-T shows safety, efficacy in treating advanced SCLC patients

The experimental "smart-bomb" drug rovalpituzumab tesirine (Rova-T) appears safe and shows efficacy in treating patients with advanced small cell lung cancer (SCLC), according to results from a first-in-human clinical trial to be presented today by a Memorial Sloan Kettering Cancer Center researcher at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago.

6 Jun 2016

Nivolumab drug shows better response rate in metastatic bladder cancer patients

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.

6 Jun 2016

Mastectomy followed by standard therapy improves survival in stage IV breast cancer patients

Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by the standard combination of therapies, adds months to the patients' lives, compared with standard therapy alone, an international clinical trial led by a University of Pittsburgh Cancer Institute professor revealed.

4 Jun 2016

Researchers detect vascular matrix stiffening during early stages of pulmonary hypertension

Pulmonary hypertension is an abnormal elevation of pressure in the pulmonary circulation that results in stress on the heart and remodeling of blood vessels in the lung.

3 Jun 2016

New mouse model allows researchers to evaluate CD40-antibody drugs effectively

Cancer immunotherapies--drugs that work by making a patient's immune system better at spotting and destroying tumor cells--are increasingly generating headlines. A number of these drugs are now being used for the treatment of melanoma, lung, and kidney cancers, and are showing promise in clinical trials with other diseases as well.

3 Jun 2016

Black men with high degree of West African genetic ancestry have less central adiposity

Among black men, those with more genetic variants descended from West Africa may have a relatively lower risk of being overweight, obese and diabetic, according to a new study out of the University of Alabama at Birmingham and University of Arizona.

2 Jun 2016

Advanced imaging kit Netspot gets FDA approval to detect rare neuroendocrine tumors

The U.S. Food and Drug Administration today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging.

2 Jun 2016

Nivolumab and ipilimumab combination could lead to effective treatment options for SCLC patients

Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that has no effective treatment options.

2 Jun 2016

New HET wearable system may help track user’s wellness to predict asthma attacks

Researchers have developed an integrated, wearable system that monitors a user's environment, heart rate and other physical attributes with the goal of predicting and preventing asthma attacks.

2 Jun 2016

FDA approves blood-based cobas EGFR Mutation Test v2 for NSCLC patients

The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients.

2 Jun 2016

Correcting defective p73 gene function may be promising therapeutic strategy for chronic lung diseases

Rising global air pollution and increasing smoking prevalence in many developing nations will likely lead to a growing incidence of lung diseases such as chronic obstructive pulmonary disease (COPD), which currently affects more than 330 million people worldwide, is the third-leading cause of death and carries an estimated healthcare cost of $2.1 trillion.

2 Jun 2016

Lungs News and Research

Existing immunotherapy drug pembrolizumab shows promise for specific sarcoma subtypes

Study shows aggressive end-of-life care for young cancer patients may be less effective

Disruptive sleep patterns could raise heart disease risk in shift workers and insomniacs

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Researchers find increased cancer incidence among patients with primary immunodeficiency disorders

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

Combination therapy equally good at treating small cell lung cancer

Experimental drug Rova-T shows safety, efficacy in treating advanced SCLC patients

Nivolumab drug shows better response rate in metastatic bladder cancer patients

Mastectomy followed by standard therapy improves survival in stage IV breast cancer patients

Researchers detect vascular matrix stiffening during early stages of pulmonary hypertension

New mouse model allows researchers to evaluate CD40-antibody drugs effectively

Black men with high degree of West African genetic ancestry have less central adiposity

Advanced imaging kit Netspot gets FDA approval to detect rare neuroendocrine tumors

Nivolumab and ipilimumab combination could lead to effective treatment options for SCLC patients

New HET wearable system may help track user’s wellness to predict asthma attacks

FDA approves blood-based cobas EGFR Mutation Test v2 for NSCLC patients

Correcting defective p73 gene function may be promising therapeutic strategy for chronic lung diseases

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News